Literature DB >> 15308589

Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.

Masaki Fujieda1, Hiroshi Yamazaki, Tetsuya Saito, Kazuma Kiyotani, Maxwell Afari Gyamfi, Masaharu Sakurai, Hirotoshi Dosaka-Akita, Yuichi Sawamura, Jun Yokota, Hideo Kunitoh, Tetsuya Kamataki.   

Abstract

We reported previously that subjects homozygous for the cytochrome P450 2A6 (CYP2A6) (*)4 have a lower risk of lung cancer. The purpose of this study was to clarify whether or not the alterations of smoking behavior and risk for lung cancer could be found in subjects possessing novel CYP2A6 variants discovered recently. An epidemiological study was performed with 1094 cases and 611 controls in male Japanese smokers. It was found that the amounts of daily cigarette consumption in subjects who harbored CYP2A6(*)4/(*)7, (*)4/(*)10, (*)7/(*)7, (*)7/(*)9 and (*)4/(*)4 genotypes were significantly less than those in subjects carrying the (*)1/(*)1 genotype (P < 0.01). Even after adjustment with cigarette consumption, the adjusted odds ratios (ORs) for lung cancer were significantly lower in subjects who harbored CYP2A6(*)1/(*)4, (*)1/(*)7, (*)1/(*)9, (*)1/(*)10, (*)4/(*)4, (*)4/(*)7, (*)4/(*)9, (*)7/(*)7 and (*)7/(*)9 genotypes than those who possessed the (*)1/(*)1 genotype (P < 0.05). When participants were classified into four groups according to the CYP2A6 genotypes, group 1 ((*)1/(*)1), group 2 (heterozygotes for the (*)1 and a variant allele), group 3 (heterozygotes and homozygotes for variant alleles except for (*)4/(*)4) and group 4 ((*)4/(*)4), lung cancer risk was found to be less in subjects with the variant of CYP2A6 alleles [group 2, OR of 0.59 [95% confidence interval (CI), 0.44-0.79]; group 3, OR of 0.52 (95% CI, 0.37-0.72); group 4, OR of 0.30 (95% CI, 0.16-0.57)]. The reduced risk for lung cancer was seen more clearly in heavy smokers than in light smokers. Additional stratification analysis showed that the ORs for squamous cell carcinoma (OR of 0.07) and small cell carcinoma (OR of 0.10) were lower than that of adenocarcinoma (OR of 0.39) in group 4. These results suggest that the CYP2A6 is one of the principal determinants affecting not only smoking behavior but also susceptibility to tobacco-related lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308589     DOI: 10.1093/carcin/bgh258

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  55 in total

1.  Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers.

Authors:  Tao Liu; Sean P David; Rachel F Tyndale; Hui Wang; Xue-Qing Yu; Wei Chen; Qian Zhou; Wei-Qing Chen
Journal:  Ann Behav Med       Date:  2012-04

2.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

3.  CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Authors:  Catherine A Wassenaar; Qian Zhou; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2015-12-15       Impact factor: 2.533

Review 4.  Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.

Authors:  Cristina Rodriguez-Antona; Alvin Gomez; Maria Karlgren; Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Hum Genet       Date:  2009-10-08       Impact factor: 4.132

5.  CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations.

Authors:  Catherine A Wassenaar; Yuanqing Ye; Qiuyin Cai; Melinda C Aldrich; Joanne Knight; Margaret R Spitz; Xifeng Wu; William J Blot; Rachel F Tyndale
Journal:  Carcinogenesis       Date:  2014-11-21       Impact factor: 4.944

6.  Cigarette consumption and biomarkers of nicotine exposure during pregnancy and postpartum.

Authors:  Taraneh Taghavi; Christopher A Arger; Sarah H Heil; Stephen T Higgins; Rachel F Tyndale
Journal:  Addiction       Date:  2018-07-23       Impact factor: 6.526

7.  From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.

Authors:  Naji C Salloum; Erica L F Buchalter; Swati Chanani; Gemma Espejo; Mahjabeen S Ismail; Randy O Laine; Maysaa Nageeb; A Benjamin Srivastava; Nicholas Trapp; Ludwig Trillo; Erica Vance; Michael Wenzinger; Sarah M Hartz; Sean P David; Li-Shiun Chen
Journal:  Pharmacogenomics       Date:  2018-06-19       Impact factor: 2.533

8.  CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.

Authors:  Jian-Min Yuan; Heather H Nelson; Steven G Carmella; Renwei Wang; Jacquelyn Kuriger-Laber; Aizhen Jin; Jennifer Adams-Haduch; Stephen S Hecht; Woon-Puay Koh; Sharon E Murphy
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

Review 9.  Smoking cessation: significance and implications for children.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

10.  Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Authors:  Taku Nagano; Makiko Shimizu; Kazuma Kiyotani; Tetsuya Kamataki; Ryohji Takano; Norie Murayama; Fumiaki Shono; Hiroshi Yamazaki
Journal:  Int J Environ Res Public Health       Date:  2010-07-20       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.